Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

DKFZ uses Roche’s xCELLigence to quantify cell proliferation

A study conducted by a team of researchers in the Heidelberg German Cancer Research Center (DKFZ) used Roche's xCELLigence MP Instrument to quantify human kinome RNAi for assaying the effects of large numbers of different small interfering RNA (siRNA) transfections with electrical impedance as output.

The study is conducted at DKFZ’s Molecular Genome Analysis division and is led by Stefan Wiemann and Ulrich Tschulena.

The xCELLigence MP Instrument utilizes a proprietary software and E-Plates 96 to measure electronic cell impedance using sensor electrodes.

Computer-controlled signal generation and automatic frequency scanning, enable continual detection of changes in cell behavior using 96-well culture plates.

The impedance measures cell number, quality of the cells’ interaction with their substrate and aids to assess cell status, including cell morphology, cell adhesion and cell viability.

The study demonstrated that xCELLigence System measurements correlate with results obtained using endpoint analysis of Promega’s CellTiter-Blue and Roche’s WST-1 Cell Proliferation Reagent for assaying cell viability, as well as qRT-PCR for quantifying gene expression.

The data obtained with the xCELLigence System allowed to identify the timing after transfection where the effect was maximal and to sort genes according to these time points.

DKFZ Division Molecular Genome Analysis head Stefan Wiemann said the data establish the technology of the xCELLigence system is suitable for high-throughput screening of phenotypes induced by RNAi and other perturbations.